Granted Patent
B2
US 12,371,685 · App. 18/340,786 · Granted Jul 29, 2025
PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
Inventors:
Ge Wei (San Diego, CA); H. Michael Shepard (Eugene, OR); Qiping Zhao (San Diego, CA); Robert James Connor (Oceanside, CA)
Assignee:
HALOZYME, INC.
C12N9/2474A61K9/0019A61K38/28A61K38/47A61K45/06A61K47/10A61P35/00C07K14/47C12Q1/34C12Y302/01035A61K38/00C07K2319/30G01N2333/926G01N2333/928Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Claims (17)
1. A modified PH20 polypeptide comprising an amino acid sequence, wherein:
(a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in the amino acid sequence of SEQ ID NO: 35 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence set forth in the amino acid sequence of SEQ ID NO: 35 to maximize identical residues, and wherein terminal gaps are treated as non-identical; and
(b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 324 with reference to amino acid positions set forth in the amino acid sequence of SEQ ID NO: 3; and
(c) the modification at position 324 is a replacement selected from among D, N, and R, and wherein the modified PH20 polypeptide exhibits increased hyaluronidase activity compared to the hyaluronidase activity of the polypeptide set forth in the amino acid sequence of SEQ ID NO: 3, measured under identical conditions.
2. The modified PH20 polypeptide of claim 1 , wherein the amino acid modification is at a position corresponding to position 324 with reference to amino acid positions in the amino acid sequence of SEQ ID NO: 3 is D.
3. The modified PH20 polypeptide of claim 2 , wherein at least 96% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in the amino acid sequence of SEQ ID NO: 35, and comprises D at a position corresponding to position 324 in the amino acid sequence of SEQ ID NO.: 3.
4. The modified PH20 polypeptide of claim 1 , wherein the hyaluronidase activity of the modified PH20 polypeptide is at least 120% of the hyaluronidase activity of the PH20 polypeptide of SEQ ID NO: 3, measured under identical conditions.
5. The modified PH20 polypeptide of claim 1 , wherein the modified PH20 polypeptide is soluble.
6. The modified PH20 polypeptide of claim 1 , further comprising one or more modifications on the polypeptide selected from among glycosylation, sialylation, albumination, farnesylation, carboxylation, hydroxylation, and phosphorylation.
7. The modified PH20 polypeptide of claim 6 , wherein the modified polypeptide is glycosylated.
8. The modified PH20 polypeptide of claim 7 , wherein the glycosylated modified PH20 polypeptide comprises an N-acetylglucosamine moiety linked to each of at least three asparagine (N) residues.
9. A pharmaceutical composition, comprising the modified PH20 polypeptide of claim 1 .
10. A method for manufacture of the modified PH20 polypeptide of claim 1 , comprising:
preparing a plasmid DNA containing cDNA encoding the modified PH20 polypeptide;
transfecting the plasmid into an isolated host cell;
culturing the cell under conditions for expression of the modified PH20 polypeptide; and
harvesting the modified PH20 polypeptide from the culture.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 28, 2023
From: SHEPARD, H. MICHAEL
To: HALOZYME, INC.
Reel/Frame 064097/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 28, 2023
From: WEI, GE; ZHAO, QIPING; CONNOR, ROBERT JAMES
To: HALOZYME THERAPEUTICS, INC.
Reel/Frame 064097/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 28, 2023
From: HALOZYME THERAPEUTICS, INC.
To: HALOZYME, INC.
Reel/Frame 064097/0374 →
Continuity (17)
Provisional Application
61796208
· Nov 1, 2012
Provisional Application
61631313
· Dec 30, 2011
References Cited (400)
US 3536809A
· Applezweig
· 1970
[cited by applicant]
US 3598123A
· Zaffaroni
· 1971
[cited by applicant]
US 3630200A
· Higuchi
· 1971
[cited by applicant]
US 3710795A
· Higuchi et al.
· 1973
[cited by applicant]
US 3845770A
· Theeuwes et al.
· 1974
[cited by applicant]
US 3916899A
· Theeuwes et al.
· 1975
[cited by applicant]
US 4002531A
· Royer
· 1977
[cited by applicant]
US 4008719A
· Theeuwes et al.
· 1977
[cited by applicant]
US 4044126A
· Cook et al.
· 1977
[cited by applicant]
US 4179337A
· Davis et al.
· 1979
[cited by applicant]
US 4364923A
· Cook et al.
· 1982
[cited by applicant]
US 4414209A
· Cook et al.
· 1983
[cited by applicant]
US 4769027A
· Baker et al.
· 1988
[cited by applicant]
US 4952496A
· Studier et al.
· 1990
[cited by applicant]
US 4980286A
· Morgan et al.
· 1990
[cited by applicant]
US 5033252A
· Carter
· 1991
[cited by applicant]
US 5052558A
· Carter
· 1991
[cited by applicant]
US 5059595A
· Le Grazie
· 1991
[cited by applicant]
US 5073543A
· Marshall et al.
· 1991
[cited by applicant]
US 5120548A
· McClelland et al.
· 1992
[cited by applicant]
US 5122614A
· Zalipsky
· 1992
[cited by applicant]
US 5323907A
· Kalvelage
· 1994
[cited by applicant]
US 5324844A
· Zalipsky
· 1994
[cited by applicant]
US 5446090A
· Harris
· 1995
[cited by applicant]
US 5591767A
· Mohr et al.
· 1997
[cited by applicant]
US 5612460A
· Zalipsky
· 1997
[cited by applicant]
US 5639476A
· Oshlack et al.
· 1997
[cited by applicant]
US 5643575A
· Martinez et al.
· 1997
[cited by applicant]
US 5672662A
· Harris et al.
· 1997
[cited by applicant]
US 5674533A
· Santus et al.
· 1997
[cited by applicant]
US 5721348A
· Primakoff et al.
· 1998
[cited by applicant]
US 5733566A
· Lewis
· 1998
[cited by applicant]
US 5766581A
· Bartley et al.
· 1998
[cited by applicant]
US 5795569A
· Bartley et al.
· 1998
[cited by applicant]
US 5808096A
· Zalipsky
· 1998
[cited by applicant]
US 5854046A
· Au-Young et al.
· 1998
[cited by applicant]
US 5900461A
· Harris
· 1999
[cited by applicant]
US 5919455A
· Greenwald et al.
· 1999
[cited by applicant]
US 5932462A
· Harris et al.
· 1999
[cited by applicant]
US 5958750A
· Au-Young et al.
· 1999
[cited by applicant]
US 5985263A
· Lee et al.
· 1999
[cited by applicant]
US 5990237A
· Bentley et al.
· 1999
[cited by applicant]
US 6057110A
· Au-Young et al.
· 2000
[cited by applicant]
US 6113906A
· Greenwald et al.
· 2000
[cited by applicant]
US 6193963B1
· Stern et al.
· 2001
[cited by applicant]
US 6214966B1
· Harris
· 2001
[cited by applicant]
US 6258351B1
· Harris
· 2001
[cited by applicant]
US 6340742B1
· Burg et al.
· 2002
[cited by applicant]
US 6413507B1
· Bentley et al.
· 2002
[cited by applicant]
US 6420339B1
· Gegg et al.
· 2002
[cited by applicant]
US 6437025B1
· Harris et al.
· 2002
[cited by applicant]
US 6448369B1
· Bentley et al.
· 2002
[cited by applicant]
US 6461802B1
· Van Thillo et al.
· 2002
[cited by applicant]
US 6461863B1
· Jarvis
· 2002
[cited by applicant]
US 6495659B2
· Bentley et al.
· 2002
[cited by applicant]
US 6615063B1
· Ntziachristos et al.
· 2003
[cited by applicant]
US 6737505B2
· Bentley et al.
· 2004
[cited by applicant]
US 6828401B2
· Nho et al.
· 2004
[cited by applicant]
US 6858736B2
· Nho et al.
· 2005
[cited by applicant]
US 7105330B2
· Stern et al.
· 2006
[cited by applicant]
US 7279457B2
· Pohl et al.
· 2007
[cited by applicant]
US 7585940B2
· Skerra et al.
· 2009
[cited by applicant]
US 7767429B2
· Bookbinder et al.
· 2010
[cited by applicant]
US 7781397B2
· Stern et al.
· 2010
[cited by applicant]
US 7829081B2
· Bookbinder et al.
· 2010
[cited by applicant]
US 7846431B2
· Bookbinder et al.
· 2010
[cited by applicant]
US 7871607B2
· Bookbinder et al.
· 2011
[cited by applicant]
US 8105586B2
· Bookbinder et al.
· 2012
[cited by applicant]
US 8187855B2
· Baker et al.
· 2012
[cited by applicant]
US 8202517B2
· Bookbinder et al.
· 2012
[cited by applicant]
US 8257699B2
· Bookbinder et al.
· 2012
[cited by applicant]
US 8318154B2
· Frost et al.
· 2012
[cited by applicant]
US 8343487B2
· Baker et al.
· 2013
[cited by applicant]
US 8431124B2
· Bookbinder et al.
· 2013
[cited by applicant]
US 8431380B2
· Bookbinder et al.
· 2013
[cited by applicant]
US 8450470B2
· Bookbinder et al.
· 2013
[cited by applicant]
US 8568713B2
· Frost et al.
· 2013
[cited by applicant]
US 8580252B2
· Bookbinder et al.
· 2013
[cited by applicant]
US 8765685B2
· Bookbinder et al.
· 2014
[cited by applicant]
US 8772246B2
· Bookbinder et al.
· 2014
[cited by applicant]
US 9284543B2
· Wei et al.
· 2016
[cited by applicant]
US 9447401B2
· Wei et al.
· 2016
[cited by applicant]
US 9913822B2
· Maneval et al.
· 2018
[cited by applicant]
US 20010021763A1
· Harris
· 2001
[cited by applicant]
US 20010044526A1
· Shen
· 2001
[cited by applicant]
US 20010046481A1
· Bentley et al.
· 2001
[cited by applicant]
US 20020052430A1
· Harris et al.
· 2002
[cited by applicant]
US 20020156047A1
· Zhao
· 2002
[cited by applicant]
US 20030017108A1
· Zamora et al.
· 2003
[cited by applicant]
US 20030114647A1
· Harris et al.
· 2003
[cited by applicant]
US 20050054048A1
· Grasso et al.
· 2005
[cited by applicant]
US 20060104968A1
· Bookbinder et al.
· 2006
[cited by applicant]
US 20070067855A1
· Jarvis et al.
· 2007
[cited by applicant]
US 20090123367A1
· Bookbinder et al.
· 2009
[cited by applicant]
US 20090311237A1
· Frost
· 2009
[cited by applicant]
US 20100003238A1
· Frost et al.
· 2010
[cited by applicant]
US 20130011378A1
· Yang et al.
· 2013
[cited by applicant]
US 20130022592A1
· Vaughn et al.
· 2013
[cited by applicant]
US 20130071394A1
· Troyer et al.
· 2013
[cited by applicant]
US 20130101577A9
· Wei et al.
· 2013
[cited by applicant]
US 20140037613A1
· Bookbinder et al.
· 2014
[cited by applicant]
US 20150010529A1
· Wei
· 2015
[cited by applicant]
US 20190336587A1
· Frost et al.
· 2019
[cited by applicant]
US 20200368330A1
· Frost et al.
· 2020
[cited by applicant]
CN 102065886A
· 2011
[cited by applicant]
EP 0400472
· 1990
[cited by applicant]
EP 0822199
· 2004
[cited by applicant]
EP 1064951
· 2007
[cited by applicant]
EP 3130347
· 2019
[cited by applicant]
EP 3636752
· 2020
[cited by applicant]
EP 3785701
· 2021
[cited by applicant]
JP 2007153797
· 2007
[cited by applicant]
KR 1020200017538
· 2020
[cited by applicant]
WO WO199216640
· 1992
[cited by applicant]
WO WO1994028024
· 1994
[cited by applicant]
WO WO2000002017
· 2000
[cited by applicant]
WO WO2001087925
· 2001
[cited by applicant]
WO WO2002049673
· 2002
[cited by applicant]
WO WO2004056312
· 2004
[cited by applicant]
WO WO2005000360
· 2005
[cited by applicant]
WO WO2009128917
· 2009
[cited by applicant]
WO WO2009134380
· 2009
[cited by applicant]
WO WO2010077297
· 2010
[cited by applicant]
WO WO2010149772
· 2010
[cited by applicant]
WO WO2012136768
· 2012
[cited by applicant]
WO WO2012174478
· 2012
[cited by applicant]
WO WO2013102144
· 2013
[cited by applicant]
WO WO2015003167
· 2015
[cited by applicant]
Burgess et al. J of Cell Bio. 1990, 111:2129-2138.
[cited by examiner]
Pawson et al. 2003, Science 300:445-452.
[cited by examiner]
Alaoui-Ismaili et al., Cytokine Growth Factor Rev. 2009; 20:501-507.
[cited by examiner]
Guo et al., PNAS 2004; 101:9205-9210.
[cited by examiner]
Kim et al., Funct. Integr. Genomics, 2011; 11:507-517. DOI 10.1007/s10142-011-0220-9.
[cited by examiner]
Lin et al., Proc. Natl. Acad. Sci. U.S.A., 1993; 90:10071-10075.
[cited by examiner]
Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, filed herewith on Jun. 23, 2023, 2 pages.
[cited by applicant]
Adams, G.E. and I.J. Stratford, “Bioreductive drugs for cancer therapy: the search for tumor specificity,” Int. J. Radiat. Oncol. Biol. Phys., 29(2): 231-238 (1994).
[cited by applicant]
Alexander et al., “Expression of the c-myc oncogene under control of an immunoglobulin enhancer in Eμ-myc transgenic mice,” Mol. Cell. Biol. 7(4):1436-1444 (1987).
[cited by applicant]
Ansel, H. C., Introduction to Pharmaceutical Dosage Forms, Lea & Febiger, Philadelphia, PA, Fourth Edition, p. 126 (1985).
[cited by applicant]
Anttila et al., “High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer,” Cancer Res. 60(1):150-155 (2000).
[cited by applicant]
Arming et al., “In vitro mutagenesis of PH-20 hyaluronidase from human sperm,” Eur. J. Biochem. 247(3):810-814 (1997).
[cited by applicant]
Atkinson, M. and E. Leiter, “The NOD mouse model of type 1 diabetes: as good as it gets?” Nature Med. 5:601-604 (1999).
[cited by applicant]
Auvinen et al., “Hyaluronan in Peritumoral Stroma and Malignant Cells Associates with Breast Canccr Sprcading and Prcdicts Survival,” Am. J. Pathol. 156(2):529-536 (2000).
[cited by applicant]
Baumgartner et al., “Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase,” Reg. Cancer Treat. 1:55-58 (1988).
[cited by applicant]
Beckenlehner et al., “Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo,” J. Cancer Res. Oncol. 118:591-596 (1992).
[cited by applicant]
Benhar et al., “Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner,” J. Biol. Chem. 269:1…
[cited by applicant]
Bianchi et al., “Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease,” Anal. Biochem. 237: 239-244 (1996).
[cited by applicant]
Bittcr ct al., “Exprcssion and sccrction vcctors for ycast,” Mcthods in Enzymol. 153:516-544 (1987).
[cited by applicant]
Bonner, W. and E. Cantey, “Colorimetric method for determination of serum hyaluronidase activity,” Clin. Chim. Acta 13:746-752 (1966).
[cited by applicant]
Bookbinder et al., “A recombinant human enzyme for enhanced interstitial transport of therapeutics,” J. Control. Release, 114:230-241 (2006).
[cited by applicant]
Bordier, C., “Phase separation of integral membrane proteins in Triton X-114 solution,” J. Biol. Chem. 256(4):1604-1607 (1981).
[cited by applicant]
Bouffard et al., “An in vitro assay for hepatitis C virus NS3 serine proteinase,” Virology 209:52-59 (1995).
[cited by applicant]
Brinster et al., “Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs,” Nature 296:39-42 (1982).
[cited by applicant]
Brown et al., “Codon utilisation in the pathogenic yeast, Candida albicans,” Nucleic Acids Res. 19(15):4298 (1991).
[cited by applicant]
Brumeanu et al., “Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements,” J. Immunol. 154:3088-3095 (1995).
[cited by applicant]
Caliceti, P. and Veronese, F. M., “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates,”Adv. Drug Deliv. Rev. 55(10):1261-1277 (2003).
[cited by applicant]
Carrillo, H. and Lipman, D., “The multiple sequence alignment problem in biology,” SIAM J. Applied Math. 48(5):1073-1082 (1988).
[cited by applicant]
Cefalu, W., “Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition,” ILAR Journal 47(3):186-198 (2006).
[cited by applicant]
Chapman et al., “Therapeutic antibody fragments with prolonged in vivo half-lives,” Nature Biotech. 17:780-783 (1999).
[cited by applicant]
Cheng et al., “PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route,” Pharm. Res. 20(9):1444-1451 (2003).
[cited by applicant]
Cherr et al., “The dual functions of GPI-anchored PH-20: hyaluronidase and intracellular signaling,” Matrix Biol., 20(8):515-525 (2001).
[cited by applicant]
Cherr et al., “The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity,” Dev. Biol. 175:142-153 (1996).
[cited by applicant]
Cho et al., “Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity,” J. Virol. Meth. 65:201-207 (1997).
[cited by applicant]
Chowpongpang et al., “Cloning and characterization of the bovine testicular PH-20 hyaluronidase core domain,” Biotechnol. Lett. 26(15):1247-52 (2004).
[cited by applicant]
Colbere-Garapin et al., “A new dominant hybrid selective marker for higher eukaryotic cells,” J. Mol. Biol. 150:1-14 (1981).
[cited by applicant]
Conserved domain search from U.S. Appl. No. 10/795,095 of SEQ ID No. 6, Primakoff et al. U.S. Pat. No. 5,721,348, performed on the NCBI website on Aug. 5, 2008.
[cited by applicant]
Csoka et al., “Hyaluronidases in tissue invasion,” Invasion Metastasis 17:297-311 (1997).
[cited by applicant]
Csoka et al., “Purification and microsequencing of hyaluronidase isozymes from human urine,” FEBS Lett., 417(3):307-310 (1997).
[cited by applicant]
Csoka et al., “The six hyaluronidase-like genes in the human and mouse genomes,” Matrix Biol. 20:499-508 (2001).
[cited by applicant]
Czejka et al., “Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients,” Pharmazie 45(9):693-694 (1990).
[cited by applicant]
De Maeyer, E. and J. De Maeyer-Guignard, “The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and poly morphism,…
[cited by applicant]
De Salegui et al., “A Comparison of Serum and Testicular Hyaluronidase,” Arch. Biochem. Biophys. 121:548-554 (1967).
[cited by applicant]
De Boer et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,” Proc. Natl. Acad. Sci. USA 80:21-25 (1983).
[cited by applicant]
Delpech et al., “Enzyme-linked hyaluronectin: a unique reagent for hyaluronan assay and tissue location and for hyaluronidase activity detection,” Anal. Biochem. 229:35-41 (1995).
[cited by applicant]
Derwent English abstract for Japanese Publication No. JP 2007-153797, published Jun. 21, 2007, entitled “Therapeutic Agent And Preventive Agent Of Autoimmune Disease, Inflammation, And Nervous Disease,” 3 pages.
[cited by applicant]
Dorfman, A. and M. Ott, “A turbidimetric method for the assay of hyaluronidase,” J. Biol. Chem. 172:367-375 (1948).
[cited by applicant]
D'Souza et al., “In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protcasc,” J. Gcn. Virol. 76:1729-1736 (1995).
[cited by applicant]
Duttaroy ct al., “Dcvclopment of a long-acting insulin analog using albumin fusion tcchnology,” Diabetes 54(1):251-258 (2005).
[cited by applicant]
Elder et. al., “Intra-arterial hyaluronidase in severe peripheral arterial disease,” Lancet 1(8169):648-649 (1980).
[cited by applicant]
Ernst et al., “Enzymatic degradation of glycosaminoglycans,” Crit. Rev. Biochem. Mol. Biol. 30(5):387-444 (1995).
[cited by applicant]
Eskens et al., “Enzymatic glycocalyx treatment impairs insulin-mediated recruitment of microvascular blood volume and decreases insulin sensitivity in rats,” FASEB Journal 25: 1023.13 (2011) (Abstract).
[cited by applicant]
Europcan Pharmacopocia, Chaptcr 5.1.3, “Efficacy of antimicrobial prcscrvation,” pp. 447-449 (2005).
[cited by applicant]
Fankhauser, N. and Mäser, P., “Identification of GPI anchor attachment signals by a Kohonen self-organizing map,” Bioinformatics 21(9):1846-1852 (2005).
[cited by applicant]
Felix et al., “Pegylated peptides IV. Enhanced biological activity of site-directed pegylated GRF analogs,” Int. J. Peptide Protein Res. 46:253-264 (1995).
[cited by applicant]
Few, B., “Hyaluronidase for treating intravenous extravasations,” MCN Amer. J. Matern. Child Nurs. 12(1):23 (1987).
[cited by applicant]
Filocamo et al., “Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus,” J. Virology 71:1417-1427 (1997).
[cited by applicant]
Forsburg, S.L., “Codon usage table for Schizosaccharomyces pombe,” Yeast 10(8):1045-1047 (1994).
[cited by applicant]
Fransson et al., “Solvent effects on the solubility and physical stability of human insulin-like growth factor I,” Pharm. Res. 14(5):606-12 (1997).
[cited by applicant]
Frost, G. I. and Stern, R., “A microtiter-based assay for hyaluronidase activity not requiring specialized reagents,” Anal. Biochem. 251:263-269 (1997).
[cited by applicant]
Gardner et al., “The complete nucleotide sequence of an infectious clone of cauliflower mosaic virus by M13mp7 shotgun sequencing,” Nucleic Acids Res. 9(12):2871-2888 (1981).
[cited by applicant]
GenBank Accession No. AAC60607, PH-20 [
[cited by applicant]
Gilbert, W. and Villa-Komaroff, L., “Useful Proteins from Recombinant Bacteria,” Scientific American 242(4):74-94 (1980).
[cited by applicant]
Girish et al., “Hyaluronidase inhibitors: a biological and therapeutic perspective,” Curr. Med. Chem. 16(18):2261-2288 (2009).
[cited by applicant]
Gmachl et al., “The human sperm protein PH-20 has hyaluronidase activity,” FEBS 336(3):545-548 (1993).
[cited by applicant]
Good et al., “Hydrogen ion buffers for biological research,” Biochemistry 5(2):467-477 (1966).
[cited by applicant]
Gribskov, M. and Burgess, R. R., “Sigma factors from
[cited by applicant]
Grosschedl et al., “Introduction of a μ immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody,” Cell 38:647-658 (1984).
[cited by applicant]
Guiotto et al., “An improved procedure for the synthesis of branched polyethylene glycols (PEGs) with the reporter dipeptide Met-βAla for protein conjugation,” Bioorg. Med. Chem. Lett. 12:177-180 (2002).
[cited by applicant]
Guntenhoner et al., “A substrate-gel assay for hyaluronidase activity,” Matrix 12:388-396 (1992).
[cited by applicant]
Guo et al., “Protein tolerance to random amino acid change,” Proc. Nat'l. Acad. Sci. USA, 101:9205-9210, 2004.
[cited by applicant]
Hahm et al., “Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity,” Virology 226:318-326 (1996).
[cited by applicant]
Haller et al., “Escaping the Interstitial Matrix With Enzyme-Mediated Drug Delivery,” Drug Delivery Technology, 5(5):1-6 (2005).
[cited by applicant]
Hamatake et al., “Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity,” Intervirology 39:249-258 (1996).
[cited by applicant]
Hammer et al., “Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements,” Science 235:53-58 (1987).
[cited by applicant]
Hanahan, D., “Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes,” Nature 315(6015):115-122 (1985).
[cited by applicant]
Harris, J. and R. Chess, “Effect of pegylation on pharmaceuticals,” Nat. Rev. Drug Discov. 2(3):214-221 (2003).
[cited by applicant]
Hartman S. and R. Mulligan, “Two dominant-acting selectable markers for gene transfer studies in mammalian cells,” Proc. Natl. Acad. Sci. 85:8047-8051 (1988).
[cited by applicant]
Have et al., “Cloning and characterization of the cDNA encoding the PH20 protein in the European red fox Vulpes vulpes,” Reproduct. Fertil. Dev. 10:165-172 (1998).
[cited by applicant]
Herrera-Estrella et al., “Expression of chimaeric genes transferred into plant cells using a Ti-plasmid-derived vector,” Nature 303:209-213 (1983).
[cited by applicant]
Herrera-Estrella et al., “Light-inducible and chloroplast-associated expression of a chimaeric gene introduced into
[cited by applicant]
Hibi et al., “Chondroitinase C activity of
[cited by applicant]
Hofinger et al., “Isoenzyme-specific differences in the degradation of hyaluronic acid by mammalian-type hyaluronidases,” Glycoconj. J. 25:101-109 (2008).
[cited by applicant]
Holash et al., “VEGF-Trap: a VEGF blocker with potent antitumor effects,” Proc. Natl. Acad. Sci. U. S. A. 99(17):11393-11398 (2002).
[cited by applicant]
Hooper, N. M., “Determination of glycosyl-phosphatidylinositol membrane protein anchorage” Proteomics 1:748-755 (2001).
[cited by applicant]
Horn et al., “Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase,” J. Surg. Oncol. 28:304-307 (1985).
[cited by applicant]
Huang et al., “Recombinant Human Hyaluronidase PH20 Does Not Stimulate an Acute Inflammatory Response and Inhibits Lipopolysaccharide-Induced Neutrophil Recruitment in the Air Pouch Model of Inflammation,” (2014) J. Imm…
[cited by applicant]
Huang, X. and W. Miller., “A time-efficient, linear-space local similarity algorithm,” Adv. Appl. Math. 12:337-357 (1991).
[cited by applicant]
Hunnicut et al., “Structural relationship of sperm soluble hyaluronidase to the sperm membrane protein PH-20,” Biol. Reprod. 54(6):1343-1349 (1996).
[cited by applicant]
Infante et al., “Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours,” Br. J. Cancer 118(2):153-161 (2018).
[cited by applicant]
Ito et al., “Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus,” J. Gen. Virol. 77:1043-1054 (1996).
[cited by applicant]
IUPAC-IUB Commission on Biochemical Nomenclature, “A One-Letter Notation for Amino Acid Scqucnccs: Tcntative Rulcs,” J. Biol. Chcm. 243(13):3557-3559 (1968).
[cited by applicant]
IUPAC-IUB Commission on Biochemical Nomenclature, “Abbreviated nomenclature of synthetic poypeptides-polymerized amino acids-revised recommendations,” The Journal of Biological Chemistry 247(2):323-325 (1972).
[cited by applicant]
Jadin et al., “A comprehensive model of hyaluronan turnover in the mouse,” Matrix Biol. 31(2):81-89 (2012).
[cited by applicant]
Jay et al., “Construction of a general vector for efficient expression of mammalian proteins in bacteria: use of a synthetic ribosome binding site,” Proc. Natl. Acad. Sci. USA 78(9):5543-5548 (1981).
[cited by applicant]
Karvincn ct al., “Hyaluronan, CD44 and vcrsican in cpidcrmal kcratinocytc tumours,” British Journal of Dermatology 148: 86-94 (2003).
[cited by applicant]
Kelsey et al., “Species- and tissue-specific expression of human α
[cited by applicant]
Kim et al., “Sperm penetration through cumulus mass and zona pellucida,” Int. J. Dev. Biol. 52(5-6):677-682 (2008).
[cited by applicant]
Kodukula et al., “Biosynthesis of Phosphatidylinositol Glycan-anchored Membrane Proteins,” J. Biol. Chem. 266:4464-4470 (1991).
[cited by applicant]
Kohno et al., “Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality,” J. Cancer Res. Clin. Oncol. 120(5):293-297 (1994).
[cited by applicant]
Kollias et al., “Regulated expression of human
[cited by applicant]
Krumlauf et al., “Developmental regulation of α-fetoprotein genes in transgenic mice,” Mol. Cell. Biol. 5(7):1639-1648 (1985).
[cited by applicant]
Krupers et al., “Complexation of poly(ethylene oxide) with poly(acrylic acid-co-hydroxyethyl methacry late)s.” Eur. Polym J. 32(6):785-790 (1996).
[cited by applicant]
Kyte et al., “A Simple Method for Displaying the Hydropathic Character of a Protein” J. Mol. Biol. 157:105-132 (1982).
[cited by applicant]
Lalancette et al, “Characterization of an 80-kilodalton bull sperm protein identified as PH-20,” Biol. Reprod. 65(2):628-636 (2001).
[cited by applicant]
Lam et al., “The effect of benzyl alcohol on recombinant human interferon-gamma,” Pharm. Res. 14(6):725-729 (1997).
[cited by applicant]
Lammerts van Bueren et al., “The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility,” Proc. Natl. Acad. Sci. U. S. A. 105(16):6109-6114 (2008).
[cited by applicant]
Lathrop et al., “cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals,” J. Cell Biol. 111(6 Pt 2):2939-2949 (…
[cited by applicant]
Laurent, T. and J. Fraser, “Hyaluronan,” FASEB J 6:2397-2404 (1992).
[cited by applicant]
Leder et al., “Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development,” Cell 45:485-495 (1986).
[cited by applicant]
Li et al., “Importance of Glycosylation and Disulfide Bonds in Hyaluronidase Activity of Macaque Sperm Surface PH-20,” J. Androl. 23:211-219 (2002).
[cited by applicant]
Li et al., “Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8,” Structure 16(2):216-227 (2008).
[cited by applicant]
Liang et al., “Prediction of antigenic epitopes on protein surfaces by consensus scoring,” BMC Bioinformatics 10:302 (2009), 10 pages.
[cited by applicant]
Lin ct al., “A hyaluronidasc activity of the spcrm plasma mcmbranc protein PH-20 cnablcs spcrm to penetrate the cumulus cell layer surrounding the egg,” J. Cell Bio. 125(5):1157-1163 (1994).
[cited by applicant]
Lin et al., “Molecular cloning of the human and monkey sperm surface protein PH-20,” Proc. Natl. Acad. Sci. USA 90:10071-10075 (1993).
[cited by applicant]
Lipponen et al., “High stromal hyaluronan level is associated with poor differentiation and metastasis in prostatc canccr,” Euro. J. Can. 37(3):849-856 (2001).
[cited by applicant]
Locke et al., “Enhanze® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20,” Drug Deliv. 26(1):98-106 (2019).
[cited by applicant]
Louveau, I. and F. Gondret, “GH and insulin affect fatty acid synthase activity in isolated porcine adipocytes in culture without any modifications of sterol regulatory element binding protein-1 expression,” J. Endocrin…
[cited by applicant]
Lowe et al., “Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course,” Diabetes Res. Clin. Pract. 80(3):439-443 (2008).
[cited by applicant]
Lu, H. and E. Wimmer., “Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus,” Proc…
[cited by applicant]
Lu, Y. A. and Felix, A. M., “Pegylated peptides I: Solid-phase synthesis of N
[cited by applicant]
Lu, Y. A. and Felix, A. M., “Pegylated peptides II. Solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides,” Int. J. Peptide Protein Res. 43:127-138 (1994).
[cited by applicant]
M3WD76 Felca (2015, updated) Hyaluronidase/PH20 from Felis catus, 3 pages.
[cited by applicant]
Ma et al., “Fucosylation in prokaryotes and eukaryotes” Glycobiology 16(12):158R-184R (2006).
[cited by applicant]
Maa and Hsu, “Aggregation of recombinant human growth hormone induced by phenolic compounds,” Int. J. Pharm. 140(2):155-168 (1996).
[cited by applicant]
MacDonald, R. J., “Expression of the pancreatic elastase I gene in transgenic mice,” Hepatology 7(1):42S-51S (1987).
[cited by applicant]
Magram et al., “Developmental regulation of a cloned adult ß-globin gene in transgenic mice,” Nature 315:338-340 (1985).
[cited by applicant]
Marković-Housley et al., “Crystal structure of hyaluronidase, a major allergen of bee venom,” Structure 8: 1025-1035 (2000).
[cited by applicant]
Maksimenko et al., “Resistance of dextran-modified hyaluronidase to inhibition by heparin” Biochemistry (Mosc.) 66(4):456-463 (2001).
[cited by applicant]
Mammalian Gene Collection (MGC) Program Team, “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,” Proc. Natl. Acad. Sci. USA 99:16899-16903 (2002).
[cited by applicant]
McIlvaine, W. B., “A buffer solution for colorimetric comparison,” J. Biol. Chem. 49:183-186 (1921).
[cited by applicant]
Mehvar, R., “Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation,” J. Pharm. Pharmaceut. Sci. 3(1):125-136 (2000).
[cited by applicant]
Menzel, E. and C. Farr, “Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses,” Cancer Lett. 131:3-11 (1998).
[cited by applicant]
Merrifield, R. B., “Solid phase peptide synthesis. I. The synthesis of a tetrapeptide,” J. Am. Chem. Soc. 85:2149-2154 (1963).
[cited by applicant]
Meyer et al., “The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 cnzymc,” FEBS Lcttcrs 413(2):385-388 (1997).
[cited by applicant]
Michelacci, Y. M. and Dietrich, C. P., “Chondroitinase C from
[cited by applicant]
Miller et al., “Use of retroviral vectors for gene transfer and expression,” Meth. Enzymol. 217:581-599 (1993).
[cited by applicant]
Mizutani et al., “Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1-infected cell line, MT-2,” J. Virol. 70:7219-7223 (1996).
[cited by applicant]
Mizutani et al., “Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells,” Biochem. Biophys. Res. Commun. 212:906-911 (1995).
[cited by applicant]
Molineux, G., “Pegylation: engineering improved biopharmaceuticals for oncology,” Pharmacotherapy 23 (8 Pt 2):3S-8S (2003).
[cited by applicant]
Monfardini et al., “A branched monomethoxypoly(ethylene glycol) for protein modification,” Bioconjugate Chem. 6:62-69 (1995).
[cited by applicant]
Nadjsombati et al., “Dose-range developmental toxicity of rHuPH20 in mice,” Matrix Biology vol. 27, Dec. 2008, p. 23.
[cited by applicant]
Nakayama et al., “CD15 expression in mature granulocytes is determined by α1,3-fucosyltransferase IX, but in promyelocytes and monocytes by α1,3-fucosyltransferase IV,” J. Biol. Chem. 276(19):16100-16106 (2001).
[cited by applicant]
NCBI Reference Sequence XP_011728213.1,
[cited by applicant]
Needleman, S. B. and Wunsch, C. D., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 (1970).
[cited by applicant]
Nekoroski et al., “A recombinant human hyaluronidase sustained release gel for the treatment of post-surgical edema,” Int. J. Dermatol. 53(6):777-785 (2014).
[cited by applicant]
Omaetxebarria et al., “Computational approach for identification and characterization of GPI-anchored peptides in proteomics experiments,” Proteomics 7(12):1951-1960 (2007).
[cited by applicant]
Ornitz et al., “Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice,” Cold Spring Harbor Symp. Quant. Biol. 50:399-409 (1985).
[cited by applicant]
Ostresh et al., “Peptide libraries: determination of relative reaction rates of protected amino acids in competitive couplings,” Biopolymers 34:1681-1689 (1994).
[cited by applicant]
Padavattan, S., “Crystal structure determination of hyaluronidase: a major bee venom allergen, in complex with an IgG Fab fragment and purification and biophysical characterization of bovine testes hyaluronidase,” 2006,…
[cited by applicant]
Paul, A. and D. Sochart, “Improving the results of ganglion aspiration by the use of hyaluronidase,” J. Hand Surg. 22B(2):219-221 (1997).
[cited by applicant]
Paulick, M. and C. Bertozzi, “The glycosylphosphatidylinositol anchor: A complex membrane-anchoring structure for proteins,” Biochemistry 47:6991-7000 (2008).
[cited by applicant]
Pawlowski et al., “The effects of hyalurodinase upon tumor formation in BALB/c mice painted with 7,12-dimethylbenz-(α)anthracene,” Int. J. Cancer 23:105-109 (1979).
[cited by applicant]
Pcdcrscn et al., “Sym004: a novcl syncrgistic anti-cpidcrmal growth factor rcccptor antibody mixturc with superior anticancer efficacy,” Cancer Res. 70(2):588-597 (2010).
[cited by applicant]
Pham et al., “Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency,” Biotechnology and Bioengineering 84(3):332-342 (2…
[cited by applicant]
Phelps et al., “Restricted lateral diffusion of PH-20, a PI-anchored sperm membrane protein,” Science 240:1780-1782 (1988).
[cited by applicant]
Pierleoni et al., “PredGPI: a GPI-anchor predictor,” BMC Bioinformatics 9:392 (2008), 11 pages.
[cited by applicant]
Pinkert et al., “An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice,” Genes and Devel. 1:268-276 (1987).
[cited by applicant]
Pirinen et al., “Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma,” Int. J. Cancer 95: 12-17 (2001).
[cited by applicant]
Primakoff et al., “Fully effective contraception in male and female guinea pigs immunized with the sperm protein PH-20,” Nature 335:543-546 (1988).
[cited by applicant]
Prothmann et al., “Sexual size dimorphism predicts rates of sequence evolution of Sperm Adhesion Molecule 1 (SPAM1, also PH-20) in monkeys, but not in hominoids (apes including humans),” Mol. Phy. Ev. 63: 52-63 (2012).
[cited by applicant]
Readhead et al., “Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype,” Cell 48:703-712 (1987).
[cited by applicant]
Reitinger et al., “Designed human serum hyaluronidase 1 variant, HYAL14L, exhibits activity up to pH 5.9,” J. Biol. Chem. 284(29):19173-19177 (2009).
[cited by applicant]
Remmele et al., “Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry,” Pharm. Res. 15(2):200-208 (1998).
[cited by applicant]
Rhodes et al., “Transformation of maize by electroporation of embryos,” Methods Mol Biol 55:121-131 (1995).
[cited by applicant]
Richmond, T., “Precompiled codon-usage tables,” Genome Biology 1:reports 241(2000).
[cited by applicant]
Ripka et al., “Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose,” Arch. Biochem. Biophys. 249(2):533-545 (1986).
[cited by applicant]
Roberts et al., “Chemistry for peptide and protein PEGylation,” Advanced Drug Delivery Reviews 54:459-476 (2002).
[cited by applicant]
Ropponen et al., “Tumor Cell-associated Hyaluronan as an Unfavorable Prognostic Factor in Colorectal Cancer,” Cancer Research 58:342-347 (1998).
[cited by applicant]
Rosengren et al., “Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration,” AAPS J. 17(5):1144-1156 (2015).
[cited by applicant]
Sato et al., “Cloning and expression in
[cited by applicant]
Sato, H., “Enzymatic procedure for site-specific pegylation of proteins,” Adv. Drug Deliv. Rev. 54:487-504 (2002).
[cited by applicant]
Sawhney et al., “Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(α-hydroxy acid) Diacrylate Macromers,” Macromolecules 26:581-587 (1993).
[cited by applicant]
Schanté et al., “Improvement of hyaluronic acid enzymatic stability by the grafting of amino-acids,” Carbohydrate Polymers, 87(3):2211-2216 (2012).
[cited by applicant]
Scharf et al., “Heat stress promoters and transcription factors,” in Nover, L. (eds) Plant Promnoters and Transcription Factors. Results and Problems in Cell Differentiation, vol. 20. Springer, Berlin, Hcidclbcrg (1994).
[cited by applicant]
Scheithauer et al., “In vitro evaluation of the anticancer drug modulatory effect of hyaluronidase in human gastrointestinal cell lines,” Anticancer Res. 8:391-396 (1988).
[cited by applicant]
Schuller et al., “Pharmacokinetics of intrahepatic 5-fluorouracil ± preinjected hyaluronidase (Neopermease, N),” Proc. Amer. Assoc. Cancer Res. 32:173, abstract No. 1034 (1991).
[cited by applicant]
Schwartz, R. M. and Dayhoff, M. O., eds., “Matrices for Detecting Distant Relationships,” Atlas of Protein Science and Structure, National Biomedical Research Foundation, pp. 353-358 (1978).
[cited by applicant]
Schwartzman, J., “Hyaluronidase: A Review in Its Therapeutic Use in Pediatrics,” J. Pediat. 39:491-502 (1951).
[cited by applicant]
Seaton et al., “Rat sperm 2B1 glycoprotein (PH20) contains a C-terminal sequence motif for attachment of a glycosyl phosphatidylinositol anchor. Effects of endoproteolytic cleavage on hyaluronidase activity,” Biol Repro…
[cited by applicant]
Shani, M., “Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice,” Nature 314:283-286 (1985).
[cited by applicant]
Sharp et al., “Codon usage patterns in
[cited by applicant]
Sharp, P.M. and E. Cowe, “Synonymous codon usage in
[cited by applicant]
Shekhar et al., “The Matrix Reloaded: Halozyme's Recombinant Enzyme Helps Injected Drugs Spread Faster,” Chem. Biol. 14:603-604 (2007).
[cited by applicant]
Shimizu, Y. and H. Yoshikura, “Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons,” J. Virol. 68:8406-8408 (1994).
[cited by applicant]
Singh et al., “Mechanisms of m-cresol-induced protein aggregation studied using a model protein cytochrome c,” J. Pharm. Sci. 100(5):1679-1689 (2011).
[cited by applicant]
Smith, T. F. and Waterman, M. S., “Comparison of biosequences,” Advances in Applied Mathematics 2:482-489 (1981).
[cited by applicant]
St. Croix et al., “Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors,” Cancer Lett. 131(1):35-44 (1998).
[cited by applicant]
Steinkuhler et al., “Product inhibition of the hepatitis C virus NS3 protease,” Biochem. 37:8899-8905 (1998).
[cited by applicant]
Stern, R., “Devising a pathway for hyaluronan catabolismare we there yet?” Glycobiology 13:105R-115R (2003).
[cited by applicant]
Stern et al., “Hyaluronidases: their genomics, structures, and mechnisms of action,” Chem. Rev. 106: 818-839 (2006).
[cited by applicant]
Sturla et al., “Core fucosylation of N-linked glycans in leukocyte adhesion deficiency/congenital disorder of glycosylation IIc fibroblasts,” Glycobiology 15(10):924-934 (2005).
[cited by applicant]
Sudo et al., “Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography,” Antiviral Res. 32:9-18 (1996).
[cited by applicant]
Sutton, S. and D. Porter, “Development of the antimicrobial effectiveness test as USP chapter <51>,” PDA J. Pharm. Sci Technol., 56(6):300-311 (2002).
[cited by applicant]
Swift et al., “Tissue-specific expression of the rat pancreatic elastase I gene in transgenic mice,” Cell 38(3):639-646 (1984).
[cited by applicant]
Takahashi et al., “A fluorimetric Morgan-Elson assay method for hyaluronidase activity,” Anal. Biochem. 322:257-263 (2003).
[cited by applicant]
Takeshita et al., “An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C virus proteinase,” (1997) Anal. Biochem. 247:242-246.
[cited by applicant]
Taliani et al., “A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates,” Anal. Biochem. 240:60-67 (1996).
[cited by applicant]
Ten Have et al., “Cloning and characterization of the cDNA encoding the PH20 protein in the European red fox Vulpes vulpes,” Reprod. Fertil. Dev. 10(2):165-172 (1998).
[cited by applicant]
Tkalec et al., “Isolation and expression in
[cited by applicant]
Tsubery et al., “Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification.,” J. Biol. Chem. 279(37):38118-38124 (2004).
[cited by applicant]
Tsuda et al., “Substrate specificity studies of
[cited by applicant]
Tung et al., “Mechanism of infertility in male guinea pigs immunized with sperm PH-20,” Biol. Reprod. 56(5):1133-1141 (1997).
[cited by applicant]
Udenfriend, S. and Kodukula, K., “Prediction of ω site in nascent precursor of glycosylphosphatidylinositol protein,” Methods Enzymol. 250:571-582 (1995).
[cited by applicant]
UniProt Murine PH20 sequence Retrieved from: <uniprot.org/uniprot/P48794, [retrieved on Aug. 2, 2010], 5 pages.
[cited by applicant]
United States Pharmacopeia. USP <51>. Antimicrobial effectiveness testing. United States Pharmacopeia Convention, Inc, Rockville, MD. Retrieved from: www.pharmacopeia.cn/v2920/usp29nf24s0_c51.html, [retrieved on Apr. 2,…
[cited by applicant]
USP XXII-NF XVII (1990), p. 644-645 United States Pharmacopeial Convention, Inc, Rockville, MD.
[cited by applicant]
Varela et al., “Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRMI in renal carcinoma,” Nature 469(7331):539-542 (2011).
[cited by applicant]
Veronese et al., “Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates,” J. Bioactive Compatible Polymers 12…
[cited by applicant]
Von Sivaraman Padavattan (2006) Thesis of University of Basel, “Crystal structure determination of hyaluronidase, a major bee venom allergen, in complex with an IgG Fab fragment and purification and biophysicial charcte…
[cited by applicant]
Wagner et al., “Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1,” Proc. Natl. Acad. Sci. USA 78(3):1441-1445 (1981).
[cited by applicant]
Wang et al., “The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis,” J. Biol. Chem. 275(19):14717-14721 (2000).
[cited by applicant]
Watson et al., Molecular Biology of the Gene, 4th Edition, The Benjamin/Cummings Pub. Co., Menlo Park, CA, p. 224 (1987).
[cited by applicant]
Weiss et al., “Activities of monomeric insulin analogs at position A8 are uncorrelated with their thermodynamic stabilities,” J. Biol. Chem. 276(43):40018-40024 (2001).
[cited by applicant]
Wells, J.A., “Additivity of Mutational Effects in Proteins,” Biochem. 29(37):8509-8517 (1990).
[cited by applicant]
White et al., “Comparison of the glycosyl-phosphatidylinositol cleavage/attachment site between mammalian cells and parasitic protozoa,” J. Cell Sci. 113(Pt.4):721-727 (2000).
[cited by applicant]
Wiglcr ct al., “Transfcr of purificd hcrpes virus thymidinc kinasc gcnc to culturcd mousc cclls,” Cell 11:223-232 (1977).
[cited by applicant]